

Papua New Guinea Support for Measles-Rubella Vaccine

This Decision Letter sets out the Programme Terms

1. Country: Papua New Guinea		
2. Grant number: 19-PNG-34a-X, 19-PNG-35a-Y		
3. Date of Decision Letter: 12 March 2019		
4. Date of the Partnership Framework Agreement (PFA): 29 November 2013		
5. Programme title: NVS Measles-Rubella Follow-up Campaign and Operational cost		
6. Vaccine type: Measles Rubella		
7. Requested product presentation and formulation of vaccine: Measles Rubella (10 doses/vial, lyo)		
8. Programme duration¹: 2019		
9. Programme Budget (indicative): (subject to the terms of the PFA, if applicable)		
	2019	Total²
Programme Budget – Campaign (US\$)	865,000	865,000
10. Indicative Annual Amounts: (subject to the terms of the PFA, if applicable) ³		
Type of supplies to be purchased with Gavi funds in each year (Campaign)	2019	
Number of Measles Rubella vaccines doses	1,328,500	
Annual Amounts (US\$)	865,000	
11. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
12. Self-procurement: Not applicable.		
13. Co-financing obligations for routine: Not applicable		

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

14. Co-financing obligations for campaign: Reference code: 19-PNG-34a-X-C

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds each year	2019
Number of vaccine doses	70,000
Number of AD syringes	-
Number of re-constitution syringes	-
Number of safety boxes	-
Value of vaccine doses (US\$)	44,749
Total co-financing payments (US\$) (including freight)	46,000

15. Vaccine introduction grant (in US\$): Not applicable

16. Operational support for campaigns: total of US\$ 8,091,897. Payable up to six months before campaign. An amount of US\$ 509,188 was approved for Programme Year 2018 representing additional risk assurance costs and is included in the total amount.

17. Additional reporting requirements:

Country shall deliver the following documents by the specified due dates as part of the conditions to the approval and disbursements of the future annual amounts:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock, by end of March; Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.	31 March 2019 15 May 2019
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
To report on national and sub-national programmatic readiness using the WHO Readiness Assessment Tool (or equivalent) at the recommended time points	Starting 15 months prior to campaign date, up to 1 week before the campaign, at the recommended time points of the tool
To submit the Supplementary Immunisation Activity (SIA) technical report for Measles or Measles-Rubella campaign	Within 3 months of end of campaign
To submit the Post campaign coverage survey report for Measles or Measles-Rubella campaign	As soon as available

18. Financial clarifications: Grants to be chaneled via WHO and UNICEF, with additional support provided to WHO to support oversight of funds flowing through HSIP to provinces.

19. Other conditions: Not applicable

Signed by,

Hind Khatib-Othman

On behalf of Gavi

Hind Khatib-Othman

Managing Director, Country Programmes

12 March 2019

